Table 1.
Univariate analysis of patients infected with H1N1pdm 6B.1 and 6B.2 viruses of Baltimore and northern Taiwan in the 2015–16 season.
| Characteristic | 6B.1 (n = 49) N (%)/median (IQR) | 6B.2 (n = 19) N (%)/median (IQR) | P value |
|---|---|---|---|
| Demographics | |||
| Site | |||
| JHMI | 22 (44.9) | 0 (0) | <0.0001* |
| CGMH | 27 (55.1) | 19 (100.0) | |
| Age | |||
| In years | 34 (28–44) | 37 (32–52) | 0.20a |
| 18–49 | 40 (81.6) | 12 (63.2) | 0.12 |
| 50–64 | 6 (12.2) | 7 (36.8) | 0.04* |
| 65+ | 3 (6.1) | 0 (0) | 0.55 |
| Gender | |||
| Female | 31 (63.3) | 14 (73.7) | 0.57 |
| Male | 18 (36.7) | 5 (26.3) | |
| Ethnicity | |||
| Non-Hispanic or Latino | 47 (95.9) | 19 (100.0) | 0.99 |
| Hispanic or Latino | 2 (4.1) | 0 (0) | |
| Race | |||
| Black or African American | 16 (32.7) | 0 (0) | <0.01* |
| White | 1 (2.0) | 0 (0) | 0.99 |
| Asian | 27 (55.1) | 19 (100.0) | <0.01* |
| Other | 5 (10.2) | 0 (0) | 0.56 |
| Vaccination and exposure | |||
| Human exposure | 11 (22.4) | 2 (10.5) | 0.31 |
| Travel in last 30 days | 9 (18.4) | 6 (31.6) | 0.33 |
| Influenza vaccine | 8 (16.3) | 0 (0) | 0.09 |
| Co-morbidities and high risk | |||
| No co-morbidities | 26 (53.1) | 7 (36.8) | <0.01* |
| One co-morbidity | 15 (30.6) | 8 (42.1) | 0.4 |
| Multiple co-morbidities | 8 (16.3) | 4 (21.1) | 0.73 |
| Immunosuppressive medication | 1 (2.0) | 0 (0) | 0.99 |
| Pregnant | 1 (2.0) | 0 (0) | 0.99 |
| Disease severity | |||
| NEWS score | 3 (0–6) | 3 (0–6) | 0.81a |
| Oxygen supplementation | 2 (4.1) | 3 (15.8) | 0.13 |
| BiPAP/CPAP | 1 (2.0) | 0 (0) | 0.99 |
| Intubated | 0 (0) | 0 (0) | 0.99 |
| Pneumonia | 7 (14.3) | 7 (36.8) | 0.05* |
| Admitted or observation | 6 (12.2) | 2 (10.5) | 0.99 |
| LOS | 7.0 (1–12) | 10.0 (5–15) | 0.14a |
| ICU | 0 (0) | 0 (0) | 0.99 |
| Death | 0 (0) | 0 (0) | 0.99 |
| Follow-up due to sequala | 3 (6.1) | 1 (5.3) | 0.99 |
| Viral co-infection | 0 (0) | 0 (0) | 0.99 |
| Symptoms | |||
| Fever | 47 (95.9) | 19 (100.0) | 0.99 |
| Cough | 48 (98.0) | 19 (100.0) | 0.99 |
| Sputum | 32 (65.3) | 14 (73.7) | 0.77 |
| Increased sputum | 17 (34.7) | 6 (31.6) | 0.78 |
| Shortness of breath | 35 (71.4) | 10 (52.6) | 0.16 |
| Wheezing | 16 (32.7) | 10 (52.6) | 0.16 |
| Headache | 40 (81.6) | 18 (94.7) | 0.26 |
| Sore throat | 39 (79.6) | 15 (78.9) | 0.99 |
| Body aches | 43 (87.8) | 19 (100.0) | 0.17 |
| Runny nose | 37 (75.5) | 19 (100.0) | 0.02* |
| Sinus pain | 13 (26.5) | 1 (5.3) | 0.091 |
| Fatigue | 43 (87.8) | 18 (94.7) | 0.66 |
| Chest pain | 30 (61.2) | 8 (42.1) | 0.18 |
| Chills | 38 (77.6) | 16 (84.2) | 0.74 |
| Loss of appetite | 36 (73.5) | 16 (84.2) | 0.53 |
| Nausea/vomiting | 28 (57.1) | 12 (63.2) | 0.79 |
| Diarrhea | 10 (20.4) | 9 (47.4) | 0.04* |
| Conjunctivitis | 11 (22.4) | 2 (10.5) | 0.33 |
Statistical analysis was done using R software.
Categorical variables were compared using chi-square or Fisher's exact tests.
a
Continuous variables were compared with rank-sum test.
*
Statistical significance was set at P < 0.05 and was represented in Bold and Italics.